Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Abstract Background Phase 3 trials have shown that nintedanib reduces the decline in forced vital capacity (FVC) in patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF) with acceptable safety profiles; however, its effects on advanced IPF are unclear. We investigated the efficacy and s...

Full description

Bibliographic Details
Main Authors: Hee-Young Yoon, Sojung Park, Dong Soon Kim, Jin Woo Song
Format: Article
Language:English
Published: BMC 2018-10-01
Series:Respiratory Research
Subjects:
Idiopathic pulmonary fibrosis
Respiratory function tests
Nintedanib
Treatment outcome
Adverse effects
Online Access:http://link.springer.com/article/10.1186/s12931-018-0907-8

Internet

http://link.springer.com/article/10.1186/s12931-018-0907-8

Similar Items